Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma | Zendy

James Perry | Zendy; Normand Laperrière | Zendy; Christopher J. O’Callaghan | Zendy; Alba A. Brandes | Zendy; Johan Menten | Zendy; Claire Phillips | Zendy; Michael Fay | Zendy; Ryo Nishikawa | Zendy; J. Gregory Cairncross | Zendy; Wilson Roa | Zendy; David Osoba | Zendy; John P. Rossiter | Zendy; Arjun Sahgal | Zendy; Hal W. Hirte | Zendy; Florence Laigle–Donadey | Zendy; Enrico Franceschi | Zendy; Olivier Chinot | Zendy; Vassilis Golfinopoulos | Zendy; Laura Fariselli | Zendy; Antje Wick | Zendy; L. Feuvret | Zendy; Michael Back | Zendy; Michael Tills | Zendy; Chad Winch | Zendy; Brigitta G. Baumert | Zendy; Wolfgang Wick | Zendy; Keyue Ding | Zendy; Warren Mason | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

Author(s) -

James Perry,

Normand Laperrière,

Christopher J. O’Callaghan,

Alba A. Brandes,

Johan Menten,

Claire Phillips,

Michael Fay,

Ryo Nishikawa,

J. Gregory Cairncross,

Wilson Roa,

David Osoba,

John P. Rossiter,

Arjun Sahgal,

Hal W. Hirte,

Florence Laigle–Donadey,

Enrico Franceschi,

Olivier Chinot,

Vassilis Golfinopoulos,

Laura Fariselli,

Antje Wick,

L. Feuvret,

Michael Back,

Michael Tills,

Chad Winch,

Brigitta G. Baumert,

Wolfgang Wick,

Keyue Ding,

Warren Mason

Publication year - 2017

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1611977

Subject(s) - temozolomide , medicine , hazard ratio , radiation therapy , concomitant , chemotherapy , surgery , dacarbazine , randomization , oncology , confidence interval , randomized controlled trial

Glioblastoma is associated with a poor prognosis in the elderly. Survival has been shown to increase among patients 70 years of age or younger when temozolomide chemotherapy is added to standard radiotherapy (60 Gy over a period of 6 weeks). In elderly patients, more convenient shorter courses of radiotherapy are commonly used, but the benefit of adding temozolomide to a shorter course of radiotherapy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research